Dr. Lori A. Kunkel

Biography

 Dr. Lori A. Kunkel has served on the board of directors since October 2014. Dr. Kunkel served as Acting Chief Medical Officer for Loxo Oncology from October 2013 to October 2014. As principal of LAK 505, LLC, she is a clinical/regulatory strategic advisor to public and private biotech companies in the San Francisco, San Diego, New York and Boston areas. She currently serves on the board of directors of Curis, Inc, Tocagen and Maverick Therapeutics and is a clinical advisor to Amphvena, Atreca and Verastem. Dr Kunkel served as Chief Medical Officer at Pharmacyclics, Inc. leading integrated clinical development highlighted by the approval of IMBRUVICA. She has also served as Chief Medical Officer at Proteolix Inc. (acquired by Onyx), Syndax, and ACT Biotech. Prior to joining the international biotechnology industry in 1995, Dr. Kunkel spent ten years in academic/clinical medicine and served as a faculty member in the Division of Hematology/Oncology’s Bone Marrow Transplant Unit at University of California, Los Angeles.

Research Interest

Hematology/Oncology